ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · USD

$8.82

+0.19 (+2.2%)· Recorded snapshot

Market cap	9.3B
Revenue (ttm)	165.8M
Net income (ttm)	-992.4M
EPS (ttm)	-$0.99
Shares out	1.1B
Volume	6,312,208
Beta	0.03

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 165.8M
Net income (ttm): -992.4M
EPS (ttm): -$0.99
Market cap: 9.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-69.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IBRX indicators

Market & fundamental data

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001326110
Company name	ImmunityBio, Inc.
Country	United States
Country code	US
CUSIP number	45256X103
Earnings date	2026-11-10
Earnings time	amc
Employees	691
Employees change	11
Employees growth	1.62%
Enterprise value	$10.2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US45256X1037
Last 10-K release date	2026-02-23
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$9.3B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$8.82
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	IBRX
U.S. state	California
Website	https://immunitybio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.21%
EV/Sales	61.64x
FCF / EV yield	-2.82%
FCF yield	-3.08%
Forward EV/Sales	36.7x
Forward P/S	33.57x
P/S ratio	56.38x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-151.88%
EBITDA margin	-141.92%
Gross margin	99.34%
Operating margin	-151.88%
Pretax margin	-598.69%
Profit per employee	$-1.4M
Revenue per employee	$239,931
ROA	-30.54%
ROA (5Y)	-49.39%
ROCE	-45.63%
ROIC	-69.1%
SBC / revenue	20.7%
Tax / revenue	-0.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Gross profit growth	191.98%
Gross profit growth (Q)	93.78%
Gross profit growth 3Y	552.81%
Gross profit growth 5Y	221.16%
Net income growth years	2
Revenue growth	192.92%
Revenue growth (Q)	93.91%
Revenue growth (QoQ)	15.91%
Revenue growth 3Y	554.26%
Revenue growth 5Y	221.59%
Revenue growth quarters	9
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-6.9M
Depreciation and amortization	$16.5M
EBIT	$-251.8M
EBITDA	$-235.3M
EPS	$-0.99
FCF per share	$-0.27
Financing cash flow	$496.8M
Free cash flow	$-288.1M
Free cash flow minus SBC	$-322.4M
Gross profit	$164.7M
Income taxes	$-161,000
Investing cash flow	$-276.9M
Net borrowing	$75M
Net cash flow	$-61.2M
Net income	$-992.4M
Operating cash flow minus SBC	$-315.4M
Operating income	$-251.8M
Revenue	$165.8M
Stock-based compensation	$34.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-8.87
Book value per share	$-0.99
Interest coverage	-2.2
Long-term assets	$189.5M
Long-term liabilities	$1.6B
Net cash (debt)	$-871M
Net cash / market cap	-9.32%
Piotroski F-Score	3
Property, plant and equipment	$145.7M
Shareholders' equity	$-1B
Tangible book value	$-1.1B
Tangible book value per share	$-1.00
Total assets	$628.5M
Total cash	$357.4M
Total debt	$1.2B
Total liabilities	$1.7B
WACC	4.76%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.32
Current assets	$439M
Current liabilities	$76.7M
Current ratio	5.72
Inventory turnover	0.26
Net working capital	$12.4M
Quick ratio	5.35
Working capital	$362.3M
Working capital turnover	0.64

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-26.61%
Dividend yield	0%
Shareholder yield	-26.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.97
1D price change	2.2%
1M price change	1.78%
1M total return	1.78%
1W price change	-2.05%
1W total return	-2.05%
1Y price change	222.93%
1Y return CAGR	223.19%
1Y total return	222.93%
20-day SMA	$9.31
200-day SMA	$7.85
3M price change	22.89%
3M total return	22.89%
3Y price change	246.37%
3Y return CAGR	51.29%
3Y total return	246.37%
50-day SMA	$8.68
50-day SMA vs 200-day SMA	50over200
52-week high	$12.43
52-week high date	2026-02-25
52-week low	$1.95
52-week low date	2025-12-31
5Y price change	10.27%
5Y return CAGR	1.98%
5Y total return	10.27%
6M price change	17.83%
6M total return	17.83%
All-time high	$40.83
All-time high date	2021-03-11
All-time low	$1.21
All-time low date	2023-03-15
Average true range (ATR)	$0.69
Average volume	15.2M
Beta (1Y)	1.45
Beta (2Y)	2.01
Beta (5Y)	0.03
Change from 52-week high	-29.04%
Change from 52-week low	352.31%
Change from all-time high	-78.96%
Change from all-time low	609.92%
Change from open	2.44%
Day's gap	-0.23%
Dollar volume	$55.7M
High price	$8.82
Low price	$8.48
Monthly RSI	58.89
Open price	$8.61
Position in 52-week range	100%
Premarket change	0%
Premarket close	$8.63
Premarket price	$8.63
Previous close	$8.63
Price vs 150-day SMA	7.73%
Price vs 20-day SMA	-7.73%
Price vs 200-day SMA	9.5%
Price vs 50-day SMA	-1.05%
Relative volume	0.42
RSI	46.76
Sharpe ratio	1.56
Sharpe ratio (3Y)	1.04
Sharpe ratio (5Y)	0.52
Sortino ratio	3.05
Sortino ratio (3Y)	1.85
Sortino ratio (5Y)	0.92
Volume	6.3M
Weekly RSI	54.26
YTD price change	333.84%
YTD total return	333.84%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	406.7M
Float percentage	38.37%
Shares change (QoQ)	2.26%
Shares change (YoY)	26.61%
Shares held by insiders	27.89%
Shares held by institutions	19.87%
Shares outstanding	1.1B
Short % of float	30.51%
Short % of shares	11.71%
Short ratio	11.3 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	183

Deeper analysis on IBRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IBRX report

Is a complete IBRX research report available?

No complete published report is available for ImmunityBio, Inc. (IBRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ImmunityBio, Inc. (IBRX)

Price

Financial snapshot

Fair-value bridge

Latest news · IBRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IBRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on IBRX

Frequently asked questions